Bringing a new drug to market is a marathon of clinical trials and data analysis. However, one of the most critical hurdles often occurs outside the lab: securing an approved proprietary (brand) name.

A drug’s name isn't just about marketing; it’s about patient safety. Regulatory bodies scrutinize names to prevent look-alike/sound-alike (LASA) errors that could lead to medication mistakes. If you are a global pharmaceutical developer, you aren't just dealing with one set of rules—you’re dealing with a patchwork of international requirements.

Based on recent guidance from major health agencies, here is a breakdown of how the name approval process differs across the U.S., Europe, the UK, and Canada.

1. United States: FDA (U.S. Food and Drug Administration)

The FDA maintains a strict "one-at-a-time" policy. While some agencies allow you to hedge your bets with multiple options, the FDA prefers focus.

  • When to Submit: It is recommended to submit an Investigational New Drug (IND) name application for conditional approval at the end of Phase 2 trials.

  • The Timeline: Budget your time carefully. The review timeline for an IND name is 180 days, while the review during the NDA/BLA (New Drug Application) phase is 90 days.

  • The Strategy: Because the FDA only reviews one name at a time, Fingerpaint Branding recommends submitting your top-choice candidate only to avoid administrative delays.

2. European Union: EMA (European Medicines Agency)

The EMA offers a bit more flexibility in the early stages but requires a clear hierarchy of choice.

  • When to Submit: You can engage the EMA Name Review Group (NRG) as early as 18 months prior to your anticipated Marketing Authorization Application (MAA). The absolute deadline is four months prior to the MAA.

  • The Strategy: You may submit up to two (2) name candidates. However, you must specify which is your primary preference and which is your secondary backup upon submission.

3. United Kingdom: MHRA (Medicines and Healthcare products Regulatory Agency)

Following Brexit, the UK’s MHRA operates independently of the EMA, and their naming guidelines reflect a desire for a robust selection process.

  • When to Submit: Similar to the EMA, you can submit as early as 18 months prior to the anticipated MAA.

  • The Strategy: The MHRA allows the most "backups," permitting up to three (3) name candidates. Like the EMA, you must specify the order of preference for these candidates at the time of submission.

4. Canada: Health Canada (HC)

Health Canada’s process is more integrated into the final filing stages and is known for being particularly stringent regarding compliance.

  • When to Submit: Name candidates are submitted at the time of the New Drug Submission (NDS).

  • The Timeline: Testing is key here. Health Canada prefers the name testing process to be completed within six (6) months of the anticipated NDS.

  • The Strategy: Like the FDA, Health Canada only reviews one (1) name at a time. Be warned: HC will only accept applications that strictly comply with their published guidelines. If an application is found deficient, it will be rejected rather than negotiated.

The Key Takeaway for Global Launches

Consistency is the goal for any global brand, but the regulatory timelines and "candidate limits" vary significantly. While you might want to test three names in the UK, you must be prepared to narrow that down to a single, high-compliance candidate for the U.S. and Canadian markets.

Success in pharmaceutical naming requires a dual-track approach: creative excellence to build a brand, and rigorous regulatory intelligence to ensure that brand actually makes it to the pharmacy shelf.

To learn more about our regulatory services or speak with a branding expert, please contact us.

Author: Brittany Scott Last Updated: March 31, 2026